Pfizer Inc (NYSE:PFE)

43.93
Delayed Data
As of Sep 24
 -0.13 / -0.30%
Today’s Change
33.20
Today|||52-Week Range
44.46
+21.29%
Year-to-Date
Pfizer (PFE) Gains As Market Dips: What You Should Know
Sep 21 / Zacks.com - Paid Partner Content
Is Artificial Intelligence the Next Big Thing in Biotech?
Sep 17 / Zacks.com - Paid Partner Content
Pfizer's Pneumococcal Vaccine Gets Breakthrough Therapy Status
Sep 21 / Zacks.com - Paid Partner Content
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
Sep 14 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: JPMorgan Ups Dividend, Disney's ESPN+ Hits 1M Paid Subscribers
Sep 21 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
Sep 14 / Zacks.com - Paid Partner Content
Eli Lilly Prices Animal Health Unit IPO at $24 Per Share
Sep 20 / Zacks.com - Paid Partner Content
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Sep 14 / Zacks.com - Paid Partner Content
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
Sep 20 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
Sep 14 / Zacks.com - Paid Partner Content
J&J Files NDA for Erdafitinib in Urothelial Cancer Indication
Sep 19 / Zacks.com - Paid Partner Content
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Sep 14 / MotleyFool.com - Paid Partner Content
Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
Sep 18 / Zacks.com - Paid Partner Content
3 Lung Cancer Stocks That Could End September on a High Note
Sep 13 / MotleyFool.com - Paid Partner Content
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
Sep 18 / Zacks.com - Paid Partner Content
Pfizer's Drug Combo Betters Survival in Kidney Cancer Study
Sep 12 / Zacks.com - Paid Partner Content
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
Sep 17 / Zacks.com - Paid Partner Content
3 Small Biotech Stocks That Almost Doubled in Past Month
Sep 11 / Zacks.com - Paid Partner Content
Glaxo Seeks EU Approval for Two-Drug Regimen in First-Line HIV
Sep 17 / Zacks.com - Paid Partner Content